INSEMPRA
25.5.2023 08:01:30 CEST | Business Wire | Press release
Insempra, a biology-powered company enabling businesses to make superior products with nature, and Fibers365, a company offering chemical-free processed fibers and substrates from annual plants, today announce that they are working together to develop and scale sustainable second-generation (2G) feedstock for the commercial production of fermentation-based ingredients.
2G feedstocks, also known as lignocellulosic feedstocks, are a key area of research and development in biotechnology as the industry is facing a growing need in the application of these in fermentation processes. Fast moving consumer good companies, for example, are demanding sustainably procured raw materials. By utilizing agricultural residues, 2G feedstock has the potential to reduce greenhouse gas emissions by replacing fossil-based and de-forestation-based ingredients and consumer products. Insempra has built a broad toolbox to use feedstocks derived from agricultural wastes and also upcoming intermediates originating from carbon capture methods.
The Fibers365 patented, modular, farm level Steam Fiber Plants allow the competitive extraction of functional cellulosic fibers, lignin and sugars from multi feedstock non-wood biomass. The sugars, currently used for the generation of biogas, can be further valorized by producing high-value products via fermentation for various industrial applications.
“By working together with Insempra, we are combining our unique 2G feedstock derived from agricultural side streams with the highly advanced fermentation technology platform needed to scale and make this sustainable feedstock accessible to broader applications.” said Stefan Radlmayr, Founder and Managing Partner of Fibers365.
One of the primary challenges with 2G feedstocks is the intrinsic material stability of lignocellulosic materials. Unlike first-generation feedstocks (e.g., those derived from beets, corn, sugarcane), which contain easily accessible sugars, lignocellulosic biomass is composed of complex structures that require pre-treatment and enzymatic hydrolysis to release the sugars. Developing efficient and cost-effective pre-treatment methods and robust enzymatic cocktails for biomass deconstruction is a key challenge in the adoption of 2G feedstocks at scale.
Insempra has successfully tested Fibers365’s 2G feedstock derived from agricultural waste streams (e.g., wheat straw) with its proprietary fermentation technology platform. Insempra is using this technology for the development of speciality lipids for application in the beauty and personal care as well as nutraceuticals and food industries. In addition to speciality lipids, Insempra is also working on the production of protein fibers and high-value functional ingredients with 2G feedstocks from agricultural waste.
“Using second-generation feedstocks in our manufacturing processes has always been one of our priorities as a biology-powered business. We are tremendously excited about the potential this technology not only has for our businesses, but for the whole industry.” said Jens Klein, CEO & Founder of Insempra.
By working together, Insempra and Fibers365 tackle the challenge of scaling and aim to maximize the potential of 2G feedstocks to support their mission to manufacture at scale in collaboration with nature, thereby contributing to a more sustainable and circular future.
About Insempra
Insempra GmbH, Munich (Germany), is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.
For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.
Led by a hand-picked team of biologists, technologists, and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future.
Learn more about Insempra at insempra.bio
About Fibers365
Fibers365 GmbH, Lenningen (Germany), offers a unique, multi-feedstock biomass processing technology for annual plants to provide functional, competitive non wood biomass products such as virgin fibers for paper, packaging and textile applications as well as high value biopolymer and fertilizer side streams, produced with carbon neutral bioenergy. The products are extracted from agricultural residues such as straw by a chemical-free, regional, farm level steam explosion pulping technology, allowing easy separation of cellulosic fibers from sugars, lignin, organic acid and minerals. The use of annually regrown plants allows to compensate CO2 emissions from processing and product consumption almost instantly, by closing a yearly carbon loop.
Learn more about Fibers365 at fibers365.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
